PMID- 8891915
OWN - NLM
STAT- MEDLINE
DCOM- 19970307
LR  - 20190914
IS  - 1572-6495 (Print)
IS  - 1572-6495 (Linking)
VI  - 683
IP  - 2
DP  - 1996 Aug 30
TI  - Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine 
      (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry 
      and fluorescence polarization immunoassay.
PG  - 189-97
AB  - Studies are presented on the toxicological detection of the designer drug 
      methylenedioxyethylamphetamine [MDE, 
      rac-N-ethyl-(3,4-methylenedioxyphenyl)-propane-2-amine] in urine after a single 
      oral dose of 140 mg of MDE by GC-MS and fluorescence polarization immunoassay 
      (FPIA). After acid hydrolysis, extraction and acetylation MDE and its metabolites 
      could be detected by mass chromatography with the selected ions m/z 72, 86, 114, 
      150, 162 and 164, followed by identification of the peaks underlying full mass 
      spectra by computer library search. The following metabolites could be detected: 
      unchanged MDE and 3,4-dihydroxyethylamphetamine (DHE) for 33-62 h, 
      3,4-methylenedioxyamphetamine (MDA) for 32-36 h and 
      4-hydroxy-3-methoxyethylamphetamine (HME) for 7-8 days. 3,4-Dihydroxyamphetamine 
      (DHA), 4-hydroxy-3-methoxyamphetamine (HMA), piperonyl acetone, 
      3,4-dihydroxyphenyl acetone and 4-hydroxy-3-methoxyphenyl acetone could only be 
      detected in trace amounts within the first few hours. The Abbott TD x FPIA assay 
      amphetamine/metamphetamine II gave positive results in urine for 33-62 h. 
      Therefore, positive immunoassay results could be confirmed by the GC-MS procedure 
      which also allowed the differentiation of MDE and its homologues 
      3,4-methylenedioxymethamphetamine (MDMA) and MDA as well as other amphetamine 
      derivatives interfering with the TD x assay. Furthermore, this GC-MS procedure 
      allowed the simultaneous detection of most of the toxicologically relevant drugs.
FAU - Ensslin, H K
AU  - Ensslin HK
AD  - Pharmaceutical Institute, University of Tubingen, Germany.
FAU - Kovar, K A
AU  - Kovar KA
FAU - Maurer, H H
AU  - Maurer HH
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - J Chromatogr B Biomed Appl
JT  - Journal of chromatography. B, Biomedical applications
JID - 9421796
RN  - 0 (Amphetamines)
RN  - 0 (Designer Drugs)
RN  - 0 (Hallucinogens)
RN  - 13026-44-3 (3-O-methyl-alpha-methyldopamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 555-64-6 (alpha-methyldopamine)
RN  - 69389-97-5 (4-hydroxy-3-methoxyethylamphetamine)
RN  - 70932-35-3 (3,4-dihydroxyethylamphetamine)
RN  - ML1I4KK67B (3,4-methylenedioxyethamphetamine)
RN  - R7339QLN1C (Deoxyepinephrine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/administration & dosage/*analogs & 
      derivatives/metabolism/urine
MH  - Administration, Oral
MH  - Amphetamines/urine
MH  - Deoxyepinephrine/analogs & derivatives/urine
MH  - Designer Drugs/administration & dosage/*analysis/metabolism
MH  - Dopamine/analogs & derivatives/urine
MH  - Fluorescence Polarization Immunoassay
MH  - Gas Chromatography-Mass Spectrometry
MH  - Hallucinogens/urine
MH  - Humans
MH  - Time Factors
EDAT- 1996/08/30 00:00
MHDA- 1996/08/30 00:01
CRDT- 1996/08/30 00:00
PHST- 1996/08/30 00:00 [pubmed]
PHST- 1996/08/30 00:01 [medline]
PHST- 1996/08/30 00:00 [entrez]
AID - 0378434796001296 [pii]
AID - 10.1016/0378-4347(96)00129-6 [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Appl. 1996 Aug 30;683(2):189-97. doi: 
      10.1016/0378-4347(96)00129-6.